CSJ137

CSJ137 is an investigational drug developed by Novartis for the treatment of iron-deficiency anemia, particularly in patients with chronic kidney disease undergoing hemodialysis. It is designed to release iron from storage sites in the body, making it available for hemoglobin synthesis and thereby addressing functional iron deficiency. Mechanistically, CSJ137 acts as a bone morphogenetic protein 6 (BMP6) inhibitor and modulates hemoglobin levels. The drug has been studied primarily as an intravenous therapy in erythropoietin-treated chronic hemodialysis patients with functional iron-deficiency anemia. Clinical trials have focused on assessing its safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in increasing blood hemoglobin levels while potentially reducing the need for erythropoietin and intravenous iron supplementation[1][2][3][4][5][6].